Emergent BioSolutions Inc.
EBSUS売上高
$743M
百万USD
営業利益
$100M
百万USD
純利益
$53M
百万USD
ROE
10.1%
最新FY
EPS
$0.93
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $343M | $70M | $1.28 |
| FY2021 | Q2 | $398M | $5M | $0.09 |
| FY2021 | Q3 | - | $-33M | $-0.61 |
| FY2021 | FY | - | $231M | $4.27 |
| FY2022 | Q1 | - | $-4M | $-0.07 |
| FY2022 | Q2 | - | $-56M | $-1.13 |
| FY2022 | Q3 | - | $-76M | $-1.52 |
| FY2022 | FY | - | $-212M | $-4.22 |
| FY2023 | Q1 | - | $-183M | $-3.65 |
| FY2023 | Q2 | - | $-261M | $-5.15 |
| FY2023 | Q3 | - | $-263M | $-5.08 |
| FY2023 | FY | - | $-760M | $-14.85 |
| FY2024 | Q1 | - | $9M | $0.17 |
| FY2024 | Q2 | - | $-283M | $-5.38 |
| FY2024 | Q3 | - | $115M | $2.06 |
| FY2024 | FY | - | $-191M | $-3.60 |
| FY2025 | Q1 | $222M | $68M | $1.19 |
| FY2025 | Q2 | $141M | $-12M | $-0.22 |
| FY2025 | Q3 | $231M | $51M | $0.91 |
| FY2025 | FY | $743M | $53M | $0.93 |
| FY2026 | Q1 | $156M | $7M | $0.07 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $782M | $1.1B | $1.6B | - | - | - | - | $743M |
| 営業利益 | $106M | $124M | $90M | $114M | $434M | $353M | $-170M | $-726M | $-109M | $100M |
| 純利益 | $52M | $83M | $63M | $55M | $305M | $231M | $-212M | $-760M | $-191M | $53M |
| 総資産 | $970M | $1.1B | $2.2B | $2.3B | $2.9B | $3.0B | $3.2B | $1.8B | $1.4B | $1.3B |
| 純資産 | $596M | $912M | $1.0B | - | - | - | - | - | - | - |
| 自己資本 | - | - | - | $1.1B | $1.4B | $1.6B | $1.4B | $649M | $483M | $523M |
| 営業CF | - | $208M | $42M | $188M | $536M | $321M | $-34M | $-206M | $59M | $171M |
| EPS | $1.13 | $1.71 | $1.22 | $1.04 | $5.67 | $4.27 | $-4.22 | $-14.85 | $-3.60 | $0.93 |
| BPS | - | - | - | $20.93 | $27.15 | $32.06 | $27.68 | $12.44 | $8.89 | $10.09 |
| ROE | - | - | - | 5.0% | 21.1% | 14.3% | -15.2% | -117.1% | -39.5% | 10.1% |